Company intelligence / Profile preview

Echo Therapeutics

Iselin, New Jersey, United States

Ownership: Private
Employees: ~19
Development stage: Other

Overview

Echo Therapeutics developed non-invasive continuous glucose monitoring systems but ceased operations after filing for Chapter 7 bankruptcy in December 2016; assets acquired by Platinum Equity affiliate in 2017.[1]

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Ferndale Pharma Group, Inc.Handok Pharmaceuticals Co., Ltd.Medical Technologies Innovation Asia, Ltd.

Beyond the preview

Go deeper on Echo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Echo Therapeutics.

Explore the full profile